

# **A Clinical Framework for the Differential Diagnosis of Substance/Medication-Induced Psychotic Disorder and Primary Psychotic Disorders**

## **I. Introduction: The Diagnostic Dilemma of Comorbid Psychosis and Substance Use**

### **The Clinical Challenge**

The co-occurrence of psychosis and substance use represents one of the most common and complex diagnostic challenges in modern clinical psychiatry. Individuals presenting with a first episode of psychosis frequently have a concurrent substance use disorder, with estimates suggesting that approximately half of all such clients present for treatment with a current substance use disorder, most commonly involving cannabis and alcohol.<sup>1</sup> This high prevalence of comorbidity creates a significant diagnostic dilemma because the acute clinical presentation of a substance-induced psychosis can be phenomenologically indistinguishable from the onset of a primary psychotic disorder such as schizophrenia.<sup>2</sup> Both conditions can manifest with the cardinal symptoms of psychosis—hallucinations, delusions, and disorganized thought—making it exceedingly difficult to determine the underlying etiology in an acute care setting, such as an emergency department.<sup>2</sup> This diagnostic ambiguity is not a minor issue; it is a central challenge that has profound implications for every aspect of patient care. When a young person presents to an emergency department with new-onset psychosis and a positive toxicology screen for cannabis or amphetamines, the clinician is faced with a critical question: is this a transient, substance-induced state that will resolve with abstinence, or is this the initial presentation of a lifelong illness like schizophrenia, merely precipitated or exacerbated by substance use? The answer to this question dictates the entire course of clinical management. In the pressurized environment of acute care, where time is limited and comprehensive history is often unavailable, clinicians must navigate this uncertainty. This often leads to the adoption of a provisional diagnosis of Substance/Medication-Induced Psychotic Disorder (SIPD), a pragmatic choice that acknowledges the most immediate and verifiable factor—the

substance use.<sup>6</sup> This "diagnostic default" serves to rule out a potentially reversible cause before committing a patient to the diagnosis and long-term treatment regimen of a primary psychotic disorder. However, this initial diagnostic label, while clinically sensible, is merely the beginning of the diagnostic process, not its conclusion. The true diagnostic work unfolds over time, requiring rigorous re-evaluation that often does not occur due to systemic barriers to effective longitudinal follow-up.<sup>8</sup>

Further complicating this landscape is the dynamic and ever-evolving nature of psychoactive substances available for misuse. The diagnostic challenge is not static; it is continually shaped by the emergence of novel psychoactive substances (NPS), synthetic cannabinoids, and high-potency cannabis strains.<sup>3</sup> These substances can produce profound and atypical psychotic syndromes that closely mimic primary psychosis.<sup>9</sup> Critically, many of these newer compounds are not detected by standard hospital toxicology screens, which are often limited in scope.<sup>5</sup> This creates a scenario where a clinician may be faced with a patient presenting with florid psychosis who denies substance use and has a negative urine drug screen, yet whose condition is, in fact, substance-induced. This possibility fundamentally elevates the importance of a meticulous clinical history and the gathering of collateral information, positioning these clinical skills as superior to laboratory findings in establishing a differential diagnosis. A negative toxicology screen, therefore, does not rule out SIPD, a crucial clinical principle that must guide the assessment process.

## The Critical Importance of Accurate Differentiation

The distinction between SIPD and a primary psychotic disorder is not a matter of academic debate; it is a critical determination with far-reaching consequences for prognosis, treatment planning, and the allocation of healthcare resources.<sup>2</sup> An accurate diagnosis is paramount because the two conditions imply fundamentally different illness trajectories and require distinct management strategies.<sup>14</sup> A diagnosis of SIPD suggests a potentially time-limited course, with the expectation that symptoms will remit with sustained abstinence from the offending substance.<sup>3</sup> Treatment, therefore, focuses primarily on detoxification, achieving and maintaining abstinence, and psychoeducation about the risks of future use.<sup>6</sup>

In stark contrast, a diagnosis of a primary psychotic disorder, such as schizophrenia, implies a chronic, often lifelong illness that requires long-term, comprehensive psychiatric management, typically involving antipsychotic medication, psychosocial interventions, and ongoing support services.<sup>16</sup> Misdiagnosing a primary psychotic disorder as SIPD may lead to a failure to initiate necessary long-term treatment, resulting in repeated relapses and a worsening long-term prognosis. Conversely, misdiagnosing SIPD as schizophrenia can lead to the unnecessary and prolonged prescription of antipsychotic medications with their attendant side effects, as well as significant stigmatization and adverse social, educational, and vocational consequences for the patient.<sup>18</sup> The diagnostic label shapes the expectations of the patient, their family, and the clinical team, profoundly influencing the therapeutic alliance and the patient's life trajectory.<sup>14</sup>

## Overview of Diagnostic Entities

To navigate this complex differential, a clear understanding of the core diagnostic entities as defined by the *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision* (DSM-5-TR) is essential.

**Substance/Medication-Induced Psychotic Disorder (SIPD):** The core feature of SIPD is the presence of prominent delusions and/or hallucinations that are judged, based on evidence from the history, physical examination, or laboratory findings, to be the direct physiological consequence of a substance or medication.<sup>6</sup> The symptoms must develop during or soon after substance intoxication or withdrawal, or after exposure to a medication.<sup>3</sup> A key diagnostic criterion is that the disturbance is not better explained by an independent, primary psychotic disorder.<sup>6</sup> The substances most commonly implicated include alcohol, cannabis, phencyclidine (PCP), hallucinogens, inhalants, opioids, sedatives, hypnotics, anxiolytics, and stimulants like amphetamine and cocaine.<sup>20</sup> A wide range of prescribed medications, such as corticosteroids, anticholinergic agents, and certain antibiotics, can also induce psychosis.<sup>6</sup>

**Primary Psychotic Disorders:** This category refers to a group of disorders within the Schizophrenia Spectrum and Other Psychotic Disorders chapter of the DSM-5-TR, where psychosis is a defining feature of the illness itself, rather than a consequence of another condition or substance.<sup>19</sup> The principal disorders in this differential include:

- **Schizophrenia:** A chronic disorder characterized by a constellation of positive symptoms (delusions, hallucinations, disorganized speech), negative symptoms (e.g., avolition, affective flattening), and cognitive deficits. A diagnosis requires these symptoms to be present for a significant portion of time during a one-month period, with continuous signs of the disturbance persisting for at least six months.<sup>17</sup> A fundamental criterion for schizophrenia is that the disturbance is not attributable to the physiological effects of a substance or another medical condition.<sup>23</sup>
- **Schizophreniform Disorder:** This disorder shares the identical core symptom criteria as schizophrenia. The key distinction is duration: the episode of illness lasts at least one month but less than six months.<sup>24</sup> Like schizophrenia, the diagnosis requires the exclusion of substance-induced and medical causes.<sup>25</sup> It often serves as a provisional diagnosis for a first psychotic episode while awaiting the six-month duration mark for schizophrenia.
- **Schizoaffective Disorder:** This diagnosis is applied when a patient's illness includes both the core symptoms of schizophrenia and a major mood episode (either manic or depressive). A defining feature is the presence of delusions or hallucinations for at least two weeks in the absence of a major mood episode during the lifetime of the illness. Furthermore, symptoms meeting criteria for a mood episode must be present for the majority of the total duration of the illness.<sup>27</sup> As with other primary psychotic disorders, the disturbance must not be attributable to the effects of a substance.<sup>27</sup>
- **Brief Psychotic Disorder:** This diagnosis is characterized by the sudden onset of at least one positive psychotic symptom (delusions, hallucinations, disorganized speech, or grossly disorganized behavior) that lasts at least one day but less than one month, with an eventual full return to premorbid functioning.<sup>16</sup>

The fundamental principle that separates these two broad categories—SIPD and primary psychotic disorders—is etiology. The entire diagnostic process is an exercise in gathering sufficient evidence to determine whether the psychosis is a direct, time-limited consequence of a substance or an independent, enduring psychiatric illness.

## II. Foundational Diagnostic Principles from DSM-5-TR

The DSM-5-TR provides the formal framework for distinguishing between SIPD and primary psychotic disorders. The diagnostic logic hinges on a careful evaluation of the nature of the symptoms, their temporal relationship to substance use, their duration, and the exclusion of other potential causes. Understanding these criteria is the first step in a rigorous diagnostic assessment.

### Substance/Medication-Induced Psychotic Disorder (SIPD) Criteria (DSM-5-TR)

The diagnosis of SIPD is established by meeting a set of specific criteria that directly link the psychotic symptoms to a substance or medication.<sup>19</sup>

- **Criterion A: Core Symptoms:** The clinical presentation must include prominent hallucinations and/or delusions.<sup>19</sup> The manual notes that hallucinations should not be included if the individual has insight that they are substance-induced, though in practice, this insight is often absent during the acute episode.
- **Criterion B: Etiological Link:** There must be evidence from the patient's history, physical examination, or laboratory findings for either (1) the symptoms in Criterion A developed during, or within a month of, substance intoxication or withdrawal, or (2) the involved medication is etiologically related to the disturbance.<sup>19</sup> This criterion establishes the necessary temporal and physiological connection. The substance or medication must be known to be capable of producing psychotic symptoms.<sup>21</sup>
- **Criterion C: Exclusion of an Independent Disorder:** This is the most critical criterion for the differential diagnosis. The disturbance cannot be better explained by a psychotic disorder that is not substance- or medication-induced. The DSM-5-TR provides specific examples of evidence that would point toward an independent (primary) psychotic disorder<sup>6</sup>:
  - **Pre-existing Symptoms:** The psychotic symptoms preceded the onset of the substance or medication use.
  - **Persistence of Symptoms:** The symptoms persist for a substantial period of time (e.g., about one month) after the cessation of acute withdrawal or severe intoxication.
  - **History of Independent Episodes:** There is other evidence of an independent psychotic disorder, such as a history of recurrent episodes that were not related to substance or medication use.

- **Criterion D: Exclusion of Delirium:** The psychotic disturbance does not occur exclusively during the course of a delirium.<sup>19</sup> While delirium can involve hallucinations and delusions, it is primarily characterized by a disturbance in attention, awareness, and cognition that fluctuates in severity. If psychosis is only present within a delirium, the diagnosis would be delirium, not SIPD.
- **Criterion E: Clinical Significance:** The disturbance must cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.<sup>6</sup> This criterion ensures that transient, non-distressing perceptual changes associated with substance use are not pathologized.

## **Primary Psychotic Disorders: The Exclusionary Rule**

A defining feature of all primary psychotic disorders in the DSM-5-TR is the requirement to rule out substance use as the direct physiological cause of the symptoms. This "exclusionary rule" is the conceptual counterpart to Criterion C for SIPD.

- **Schizophrenia:** The diagnostic criteria for schizophrenia include Criterion F, which explicitly states: "The disturbance is not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication) or another medical condition".<sup>23</sup> To make a diagnosis of schizophrenia, the clinician must have sufficient evidence to confidently exclude a substance-induced etiology. This requires meeting the duration criteria (continuous signs for at least six months) and ensuring that the symptoms are not better explained by substance use.<sup>17</sup>
- **Schizophreniform Disorder:** Similarly, Criterion D for schizophreniform disorder states: "The disturbance is not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication) or another medical condition".<sup>25</sup> Given its shorter duration (one to six months), differentiating schizophreniform disorder from a persistent substance-induced psychosis (e.g., from stimulants like methamphetamine) can be particularly challenging and relies heavily on establishing a period of abstinence.<sup>20</sup>
- **Schizoaffective Disorder:** The diagnosis of schizoaffective disorder also includes Criterion D, which excludes disturbances attributable to the effects of a substance.<sup>27</sup> The complex interplay of psychotic and mood symptoms in this disorder adds another layer to the differential, as substances can induce both types of symptoms. The key is to establish that the full syndrome, including the requisite two-week period of psychosis without mood symptoms, exists independently of substance effects.<sup>27</sup>

## **The Pivotal Role of the Temporal Relationship**

Synthesizing these criteria reveals that the entire diagnostic framework rests on establishing a clear and reliable timeline of events.<sup>4</sup> The central diagnostic question that the clinician must answer is:

**Did the psychosis exist independently of the substance use?** This involves

meticulously mapping the onset, course, and offset of psychotic symptoms against the pattern of substance use, including periods of intoxication, withdrawal, and, most importantly, abstinence.

If the psychotic symptoms consistently appear only during periods of intoxication or withdrawal and remit within a reasonable timeframe (generally less than a month) following cessation of use, a diagnosis of SIPD is supported. If, however, the symptoms preceded the substance use, persist long after the substance has been eliminated from the body, or have occurred during documented periods of abstinence, the evidence shifts strongly in favor of a primary psychotic disorder. This temporal relationship is the primary, albeit often most difficult to establish, differentiating factor according to the DSM-5-TR. The clinical challenge, therefore, is not a lack of clear rules, but the difficulty in obtaining the reliable data needed to apply them.

<b>Table 1: Comparative DSM-5-TR Diagnostic Criteria for Psychotic Disorders</b>			
<b>Diagnostic Criterion</b>	<b>Substance/Medication-Induced Psychotic Disorder (SIPD)</b>	<b>Schizophreniform Disorder</b>	<b>Schizophrenia</b>
<b>A. Core Symptoms</b>	Prominent hallucinations and/or delusions. <sup>19</sup>	Two or more of: delusions, hallucinations, disorganized speech, grossly disorganized/catatonic behavior, negative symptoms. At least one must be delusions, hallucinations, or disorganized speech. <sup>25</sup>	Identical to Schizophreniform Disorder. <sup>17</sup>
<b>B. Duration</b>	Symptoms develop during or soon after intoxication/withdrawal. Can persist as long as use continues. No minimum duration required, but resolution is expected with abstinence. <sup>19</sup>	Episode lasts at least 1 month but less than 6 months. <sup>24</sup>	Continuous signs of disturbance persist for at least 6 months, including at least 1 month of active-phase symptoms. <sup>19</sup>
<b>C. Relationship to Substance Use</b>	<b>Etiological:</b> Symptoms are a direct physiological consequence of substance/medication use. Disturbance is not	<b>Exclusionary:</b> The disturbance is not attributable to the physiological effects of a substance or another	<b>Exclusionary:</b> The disturbance is not attributable to the physiological effects of a substance or another

	better explained by an independent psychotic disorder. <sup>6</sup>	medical condition. <sup>25</sup>	medical condition. <sup>23</sup>
<b>D. Functional Impairment</b>	Causes clinically significant distress or impairment in social, occupational, or other important areas of functioning. <sup>6</sup>	Not required for diagnosis, but functional decline is often present. <sup>24</sup>	For a significant portion of time since onset, level of functioning in one or more major areas (work, interpersonal relations, self-care) is markedly below the level achieved prior to onset. <sup>19</sup>
<b>E. Key Differentiator</b>	<b>Temporal and causal link to substance use.</b> Psychosis that persists for ~1 month after cessation of substance use suggests an independent disorder. <sup>6</sup>	Duration (1-6 months). Differentiated from Brief Psychotic Disorder (<1 month) and Schizophrenia (>6 months). <sup>25</sup>	<b>Duration (&gt;6 months) and characteristic functional decline.</b> Chronic course with potential for prodromal and residual phases. <sup>17</sup>

### III. The Comprehensive Clinical Evaluation: A Multi-Modal Approach

Applying the DSM-5-TR criteria effectively requires a systematic and comprehensive clinical evaluation. The diagnosis is not made from a single piece of information but is rather a conclusion drawn from the convergence of evidence from multiple sources. This multi-modal approach is essential to navigate the inherent uncertainties of comorbid psychosis and substance use.

#### The Patient History

The patient's history is the absolute cornerstone of the diagnostic process. A meticulously gathered history provides the timeline and context necessary to differentiate a substance-induced condition from a primary one.

#### Detailed Substance Use History

A superficial inquiry into substance use is insufficient. The clinician must conduct a forensic-level investigation into the patient's entire history of substance and medication use.<sup>6</sup> This involves exploring several key domains:

- **Substances Used:** It is crucial to identify all substances, including those the patient may not consider "drugs." This includes alcohol, cannabis (inquiring about frequency, potency, and use of concentrates), stimulants (cocaine, amphetamines), hallucinogens, opioids, sedatives, and inhalants.<sup>6</sup> Equally important is a thorough review of all prescribed and over-the-counter medications, as many can induce psychosis, including corticosteroids, anticholinergics, certain antibiotics, and antiparkinsonian agents.<sup>6</sup> The clinician should also inquire about novel psychoactive substances, which may not be familiar to the patient by name.<sup>3</sup>
- **Pattern of Use:** The assessment must detail the pattern of use for each substance. This includes the age of first use, the frequency (e.g., daily, weekends only), quantity consumed per occasion, and the route of administration (e.g., oral, intranasal, intravenous, smoking), as different routes can lead to more rapid and intense psychoactive effects.<sup>32</sup> The clinician needs to distinguish between periods of experimental, occasional, or heavy use.<sup>32</sup>
- **Timeline and Abstinence:** The most critical element is to construct a detailed timeline that maps the pattern of substance use against the emergence and course of psychotic symptoms.<sup>6</sup> The clinician must actively probe for any periods of sustained abstinence, defined as approximately one month or longer. Determining the patient's mental state during these substance-free periods is often the single most powerful piece of diagnostic evidence. If psychosis was absent during abstinence and only emerged with substance use, it strongly supports SIPD. Conversely, if psychosis persisted during abstinence, it points toward a primary disorder.<sup>6</sup>

## **Psychiatric and Developmental History**

The substance use history must be contextualized within the patient's broader life story.

- **Premorbid Functioning:** A careful assessment of the patient's social, academic, and occupational functioning before the onset of either heavy substance use or psychotic symptoms is essential. A history of good premorbid functioning that declines only in the context of heavy substance use may favor SIPD. In contrast, a history of long-standing social difficulties, academic underachievement, or odd behaviors that predate significant substance use is a "red flag" for a primary psychotic disorder like schizophrenia.<sup>6</sup>
- **Prodromal Symptoms:** Clinicians should inquire about subtle, attenuated symptoms that may have preceded the first florid psychotic episode. These can include increasing social withdrawal, a decline in self-care, vague or odd beliefs, unusual perceptual experiences, and a general decline in functioning.<sup>16</sup> The presence of a clear prodromal phase preceding heavy substance use strongly suggests an emerging primary illness.
- **Past Episodes:** A history of previous psychiatric episodes, particularly psychotic or major mood episodes, is critical. If any of these past episodes occurred during a documented period of abstinence, it provides strong evidence for an independent, primary disorder.<sup>6</sup>

## The Mental Status Examination (MSE)

The MSE provides a cross-sectional view of the patient's mental state at the time of evaluation.<sup>26</sup> While the presence of psychosis is the reason for the assessment, the *quality* and *pattern* of symptoms can offer diagnostic clues. For example, the clinician should note the modality of hallucinations (auditory vs. visual/tactile), the nature of delusions (bizarre vs. non-bizarre, paranoid vs. grandiose), the presence and severity of negative symptoms, and the degree of formal thought disorder versus simple confusion or disorientation. These phenomenological details, discussed further in Section IV, contribute to the overall diagnostic picture.

## Physical Examination and Laboratory Findings

A medical workup is a mandatory part of the initial evaluation to rule out other causes of psychosis and to corroborate the substance use history.

- **Toxicology Screening:** Urine and/or blood toxicology screens are standard practice. Their primary role is to confirm recent substance use and identify the specific substances involved.<sup>35</sup> However, their limitations must be understood. A positive screen confirms recent exposure but does not, by itself, prove that the substance caused the psychosis.<sup>5</sup> Many individuals with primary schizophrenia use substances, and a positive screen may simply reflect this comorbidity. Conversely, a negative screen does not rule out SJPD. The detection window for many substances is short (e.g., hours to a few days for cocaine and amphetamines), and standard screens do not test for many hallucinogens, synthetic cannabinoids, or other NPS.<sup>5</sup> Therefore, toxicology results must be interpreted in the context of the comprehensive clinical history.
- **Ruling Out Other Medical Conditions:** Psychosis can be a manifestation of numerous general medical conditions. A thorough physical and neurological examination, along with indicated laboratory tests (e.g., complete blood count, metabolic panel, thyroid function, vitamin B12/folate, syphilis/HIV serology) and neuroimaging (CT or MRI scan), is necessary to exclude etiologies such as central nervous system tumors or infections, autoimmune encephalitis, metabolic disturbances, or degenerative neurological disorders.<sup>4</sup>

## The Indispensable Role of Collateral Information

In cases of new-onset psychosis, the patient is often a poor historian due to the severity of their symptoms, cognitive impairment, paranoia, or poor insight. In this context, information from collateral sources—family members, partners, friends, previous healthcare providers, or case managers—is not merely helpful; it is often the most critical component of the diagnostic assessment.

- **Corroborating Timelines:** Family and friends are invaluable for establishing an accurate timeline of events. They can often provide a more objective account of when behavioral changes first began and how these changes related to the patient's substance use patterns.<sup>6</sup> They can answer the crucial question: "Which came first, the strange behavior or the heavy drug use?"
- **Documenting Abstinence:** Collateral informants are the most reliable source for determining if the patient has ever had a substance-free period of a month or more. They can describe the patient's mental state during such periods, providing the most direct evidence for or against an independent psychotic disorder.<sup>6</sup>
- **Family History:** A detailed, multi-generational family history of both psychiatric disorders and substance use disorders should be obtained from a reliable family member. This information carries significant diagnostic weight. The presence of schizophrenia or bipolar disorder in first-degree relatives markedly increases the likelihood of a primary psychotic disorder in the patient.<sup>15</sup> This is a powerful "soft sign" pointing toward an underlying genetic vulnerability for psychosis. However, the absence of such a history does not rule out a primary disorder, as many cases of schizophrenia are sporadic. In contrast, a dense family history of substance use disorders, particularly in parents, is a strong predictor for an SIPD diagnosis.<sup>6</sup> This suggests a potential genetic loading for addiction itself, which may be the primary driver of the clinical presentation. The clinician should therefore probe specifically and separately for both domains, as the relative weight of each provides a crucial diagnostic clue.

The systematic collection of this multi-modal data is essential. The logic embedded within structured diagnostic interviews, such as the Structured Clinical Interview for DSM-5 (SCID) or the Psychiatric Research Interview for Substance and Mental Disorders (PRISM), offers a valuable model for clinical practice.<sup>2</sup> These instruments are designed to enforce a rigorous, sequential assessment, typically by first establishing a detailed lifetime history of substance use

*before evaluating for primary psychiatric disorders.<sup>2</sup>* This structure compels the clinician to systematically consider the substance-induced explanation first and to actively seek evidence to rule it in or out before concluding that the psychosis is primary. Even without using the formal instrument, clinicians can adopt this logic in their own interviews. By first building a detailed substance use timeline and then overlaying the psychiatric symptoms onto it, they can mitigate the risk of premature diagnostic closure and ensure a more thorough and unbiased evaluation.

## IV. Key Differentiating Features in Clinical Practice

Beyond the formal diagnostic criteria and the process of evaluation, clinicians rely on recognizing patterns in the clinical presentation—the phenomenology of the illness—to guide their diagnostic reasoning. While there is significant overlap, certain features of the symptom profile, associated clinical characteristics, and substance-specific syndromes can provide valuable clues to differentiate SIPD from primary psychotic disorders.

## Symptom Profile and Phenomenology

### Positive Symptoms

- **Hallucinations:** The modality of hallucinations is a key differentiator. While auditory hallucinations are the most common type in schizophrenia, often involving voices commenting on the person's actions or conversing with one another, visual and tactile hallucinations are significantly more common and prominent in SIPD.<sup>6</sup> Patients with SIPD, particularly in the context of stimulant use or alcohol withdrawal, are more likely to report seeing things that are not there or experiencing tactile sensations, such as the classic delusion of parasitosis (formication or "cocaine bugs").<sup>13</sup> While patients with schizophrenia can have visual hallucinations, their predominance over auditory ones should raise the index of suspicion for a substance-induced or medical etiology.
- **Delusions:** The content and structure of delusions can also differ. In SIPD, delusions are frequently paranoid or persecutory in nature and are often directly related to the context of substance use (e.g., believing police are outside the door).<sup>33</sup> While these can be intense, they may be less systematized, complex, and bizarre than the delusions often seen in schizophrenia, which can involve elaborate themes of thought insertion, thought withdrawal, or control.<sup>16</sup> However, this distinction is not absolute; severe stimulant-induced psychosis, in particular, can produce bizarre delusions that are virtually indistinguishable from those of schizophrenia.<sup>33</sup>

### Negative Symptoms

The relative absence of prominent and persistent negative symptoms is one of the most robust clinical features distinguishing SIPD from schizophrenia.<sup>44</sup> Schizophrenia is often characterized by enduring negative symptoms such as avolition (lack of motivation), alogia (poverty of speech), anhedonia (inability to feel pleasure), asociality, and affective flattening (diminished emotional expression).<sup>16</sup> These symptoms contribute significantly to the functional impairment seen in the disorder. In contrast, while individuals with SIPD may appear withdrawn or unmotivated during an acute episode, these features are typically less severe and tend to resolve along with the positive symptoms once abstinence is achieved.<sup>6</sup> Studies comparing the two groups consistently find that patients with a primary psychosis have significantly higher scores on measures of negative symptoms.<sup>2</sup>

### Cognitive and Disorganization Symptoms

Schizophrenia is fundamentally a disorder of thought and cognition, often marked by a formal thought disorder (e.g., loose associations, tangentiality, incoherence) and enduring

neurocognitive deficits, particularly in executive functioning, working memory, and attention.<sup>16</sup> In SIPD, the cognitive picture is more often one of confusion, disorientation, and memory problems that are more characteristic of an acute intoxication or withdrawal state, akin to a delirium.<sup>21</sup> While speech may be disorganized, it is less likely to show the classic formal thought disorder of schizophrenia and is more likely to improve rapidly with sobriety.

## Substance-Specific Psychotic Syndromes

The clinical presentation of SIPD can vary depending on the class of substance involved.

- **Stimulant-Induced Psychosis (Amphetamine, Cocaine, Methamphetamine):** This syndrome is the classic mimic of paranoid schizophrenia. It is characterized by a predominance of positive symptoms, including intense paranoia, persecutory delusions, psychomotor agitation, and stereotyped, repetitive behaviors.<sup>33</sup> As noted, visual and tactile hallucinations are common.<sup>47</sup> While the presentation can be severe and closely resemble an acute schizophrenic episode, the relative lack of prominent negative symptoms or a formal thought disorder can be a distinguishing feature.<sup>33</sup>
- **Cannabis-Induced Psychosis:** The presentation often includes paranoia, anxiety, grandiosity, and perceptual alterations, such as a distorted sense of time.<sup>43</sup> While the psychotic symptoms can be indistinguishable from those of schizophrenia, some evidence suggests that individuals with cannabis-induced psychosis may have better premorbid functioning, better cognitive performance, and fewer negative symptoms compared to those with schizophrenia.<sup>46</sup> Cannabis use is a potent risk factor for psychosis, and this specific form of SIPD carries a particularly high risk of later conversion to a schizophrenia spectrum disorder.<sup>49</sup>
- **Hallucinogen-Induced Psychosis (LSD, Psilocybin, Mescaline):** This is primarily a disorder of perception. It is characterized by profound alterations in sensory experience, including vivid visual hallucinations, illusions, and synesthesia (e.g., "seeing sounds").<sup>52</sup> A sense of dissociation, mystical or spiritual experiences, and labile mood are also common.<sup>52</sup> While the experience can be frightening and lead to panic and paranoia, reality testing may be better preserved than in schizophrenia, and individuals may retain some awareness that their experiences are drug-induced. "Flashbacks," or the re-experiencing of perceptual distortions long after the drug has worn off, can also occur.<sup>52</sup>

## Associated Clinical Features

Beyond the core symptom profile, other clinical characteristics can help differentiate the two conditions.

- **Insight:** Insight, or the awareness of having a mental illness and understanding the nature of one's symptoms, is often a key differentiator. Anosognosia, a profound lack of insight that is a neurological symptom of the illness itself, is a hallmark of schizophrenia.<sup>16</sup> In contrast, individuals with SIPD are more likely to develop insight

into their condition once the acute effects of the substance have subsided.<sup>6</sup> They may be able to acknowledge that their psychotic experiences were unusual and directly related to their drug use. Poorer insight at baseline in a patient with comorbid substance use is a predictor that the diagnosis will ultimately be a primary psychotic disorder.<sup>15</sup>

- **Other Historical Factors:** As mentioned previously, the broader personal and family history provides critical context. Cohorts of patients with SIPD tend to have higher rates of parental substance abuse, a personal diagnosis of substance *dependence* (rather than just abuse), a forensic history, and a history of trauma when compared to cohorts with primary psychotic disorders.<sup>6</sup>

<b>Table 2: Clinical and Phenomenological Differentiators in Practice</b>		
Clinical Domain	Typical Presentation in SIPD	Typical Presentation in Primary Psychosis (Schizophrenia)
<b>Onset</b>	Acute and rapid, clearly linked to intoxication or withdrawal. <sup>42</sup>	More often insidious, with a gradual prodromal phase of functional decline and attenuated symptoms. <sup>16</sup>
<b>Predominant Hallucinations</b>	Visual and tactile hallucinations are common and often prominent. <sup>6</sup>	Auditory hallucinations (especially voices) are the most common modality. <sup>16</sup>
<b>Negative Symptoms</b>	Typically absent or mild and transient; resolve with abstinence. <sup>44</sup>	Prominent and persistent (avolition, alogia, affective flattening); a core feature of the illness. <sup>16</sup>
<b>Cognitive Symptoms</b>	Confusion, disorientation, memory impairment; often resolves with abstinence. <sup>21</sup>	Enduring deficits in executive function, working memory, and attention; formal thought disorder is common. <sup>16</sup>
<b>Insight</b>	Often improves significantly after the acute phase; patient may recognize the link to substance use. <sup>6</sup>	Often poor and persistent (anosognosia); patient may lack awareness of being ill. <sup>16</sup>
<b>Family History</b>	Higher rates of substance use disorders in the family. <sup>6</sup>	Higher rates of schizophrenia and other psychotic disorders in the family. <sup>15</sup>
<b>Premorbid Functioning</b>	Generally good, with decline associated with the onset of heavy substance use. <sup>54</sup>	Often a history of poorer social, academic, or occupational functioning preceding the onset of psychosis. <sup>6</sup>

<b>Resolution with Abstinence</b>	Symptoms typically resolve within days to weeks (generally <1 month) after cessation of substance use. <sup>20</sup>	Symptoms persist for >1 month after cessation of substance use and follow a chronic or relapsing-remitting course. <sup>6</sup>
-----------------------------------	--	---

## V. The Longitudinal Perspective: Diagnosis as an Evolving Process

The most definitive tool in the clinician's armamentarium for distinguishing SIPD from a primary psychotic disorder is time. In the acute setting, diagnostic certainty is often impossible due to the confounding effects of intoxication or withdrawal.<sup>15</sup> Therefore, the diagnostic process must be viewed as a longitudinal endeavor, where an initial provisional diagnosis is subject to revision based on the evolving clinical course and response to treatment, particularly abstinence.

### The Provisional Diagnosis

It is a fundamental principle of this differential diagnosis that any diagnosis made during an acute presentation with active substance use should be considered provisional.<sup>24</sup> The central diagnostic dilemma is the inability to observe the patient's baseline mental state in a substance-free condition.<sup>6</sup> Many individuals presenting with a first episode of psychosis have been using substances continuously for months or years, precluding any opportunity to know what they are like when sober.<sup>6</sup> In this scenario of diagnostic uncertainty, a provisional diagnosis of SIPD is often the most appropriate and conservative starting point, pending further observation.

### The Critical Role of a Documented Period of Abstinence

The single most important factor in clarifying the diagnosis is observing the patient during a documented period of sustained abstinence. This is where the "one-month rule" from the DSM-5-TR becomes a crucial clinical heuristic.<sup>6</sup> If prominent psychotic symptoms—delusions or hallucinations—persist for approximately one month or longer after the cessation of acute intoxication or withdrawal, the diagnosis of an independent, primary psychotic disorder becomes highly probable.<sup>34</sup> If, on the other hand, the symptoms resolve within this timeframe, it strongly supports the initial diagnosis of SIPD. Achieving and documenting this period of abstinence is therefore a primary goal of the initial phase of treatment. Inpatient hospitalization serves a dual purpose in this context: it provides a safe environment for stabilization and detoxification, and it creates a controlled setting for observation during a period of forced abstinence.<sup>6</sup> This period of observation is not passive; it is an active diagnostic trial. The clinical team must meticulously document the trajectory of psychotic symptoms as the substance is cleared from the patient's

system. The resolution, or persistence, of these symptoms provides the most powerful evidence for confirming or revising the initial diagnosis.<sup>34</sup>

## Diagnostic Stability and Conversion

Longitudinal studies have consistently shown that the initial diagnosis is often unstable. A significant proportion of individuals who are initially diagnosed with SIPD are later re-diagnosed with a primary psychotic disorder, most commonly schizophrenia. This phenomenon is often referred to as "diagnostic conversion."

- **Rates of Conversion:** The pooled rate of conversion from SIPD to schizophrenia is estimated to be around 25% to 35%.<sup>6</sup> However, this rate is not uniform across all substances and populations. Some studies have reported conversion rates as high as 46%.<sup>9</sup> This indicates that for a substantial minority of patients, the initial psychotic episode triggered by substance use is not a transient, self-limited event but rather the first manifestation of an enduring underlying illness.<sup>56</sup>
- **Substance-Specific Risk:** The risk of conversion varies dramatically depending on the substance that induced the initial psychosis. The evidence is strongest for cannabis, which carries the highest risk of transition to schizophrenia, with conversion rates reported between 34% and 47%.<sup>49</sup> Hallucinogens and amphetamines also confer a substantial risk, with conversion rates around 26% and 22%, respectively.<sup>49</sup> In contrast, the risk of conversion is considerably lower for psychoses induced by alcohol (around 10%), opioids (12%), and sedatives (9%).<sup>49</sup>
- **Predictors of Conversion:** Research has identified several key baseline factors that predict which individuals with an initial SIPD diagnosis are most likely to later "convert" to a diagnosis of schizophrenia. These predictors are, in essence, markers of an underlying vulnerability to psychosis<sup>6</sup>:
  - **Family History of Psychosis:** A family history of a nonaffective psychotic disorder like schizophrenia is a powerful predictor of conversion.<sup>15</sup>
  - **Poor Premorbid Functioning:** A history of poor social, academic, or occupational functioning before the onset of the psychotic episode suggests a pre-existing vulnerability.<sup>6</sup>
  - **Early Age of Onset:** A younger age at the time of the initial SIPD episode is associated with a higher risk of conversion to schizophrenia.<sup>8</sup>
  - **Male Sex:** Males appear to have a higher risk of conversion than females.<sup>9</sup>
  - **Clinical Features:** Poorer insight into the psychosis at baseline is also a predictor of later conversion.<sup>15</sup>

The evidence on diagnostic conversion leads to a more nuanced understanding of SIPD. For a significant subset of patients, the substance does not create psychosis *de novo* in a healthy brain. Instead, it acts as a biological "stress test," precipitating the onset of psychosis in an individual with a pre-existing, latent vulnerability to a primary psychotic disorder.<sup>38</sup> The predictors for conversion—family history of psychosis and poor premorbid functioning—are the same classic risk factors for developing schizophrenia in the first place. This suggests that the substance use serves as a potent environmental trigger that

unmasks this underlying diathesis. Therefore, every patient presenting with a first episode of SIPD, particularly if it was induced by cannabis or stimulants, should be considered to be at high clinical risk for the future development of schizophrenia. The diagnosis of SIPD should not be an endpoint but rather the beginning of a period of heightened surveillance, assertive follow-up, and early intervention.

This clinical progression from an acute SIPD episode to a chronic diagnosis of schizophrenia closely mirrors the leading neurodevelopmental models of the illness, such as the "two-hit" or diathesis-stress hypothesis.<sup>14</sup> This model posits a "first hit," which represents a genetic predisposition or an early neurodevelopmental insult, creating a silent vulnerability. The "second hit" is typically an environmental stressor occurring during a critical neurodevelopmental period, such as adolescence or young adulthood, which then triggers the clinical onset of the illness. In the context of this diagnostic dilemma, the family history of psychosis or poor premorbid functioning can be conceptualized as the "first hit" (the diathesis). The initiation of heavy substance use, especially adolescent cannabis use, serves as the potent "second hit" (the stressor).<sup>38</sup> The initial SIPD episode is the clinical manifestation of this "second hit" activating the underlying vulnerability. The subsequent persistence of symptoms after a period of abstinence and the eventual diagnostic conversion to schizophrenia represent the consolidation of the chronic illness course. This framework provides a powerful explanatory model for clinicians to use with patients and families, helping to explain why a substance that many people use without long-term consequence could trigger a severe and persistent illness in their specific case.

## **VI. Conclusion: Synthesizing Evidence for Clinical Decision-Making**

The differentiation of Substance/Medication-Induced Psychotic Disorder from primary psychotic disorders is a complex clinical task that demands a sophisticated, multi-faceted, and longitudinal approach. It is not a decision based on a single data point, such as a positive toxicology screen, but rather a dynamic process of evidence integration from multiple domains. The final diagnosis emerges from a careful synthesis of the temporal relationship between substance use and symptom onset, the specific phenomenology of the psychotic symptoms, comprehensive personal and family history obtained from the patient and collateral sources, and, most critically, the clinical course observed during a documented period of abstinence.

The initial evaluation in an acute care setting must be understood as the beginning of this process, with any diagnosis rendered at that time being inherently provisional. The clinician's primary task is to systematically gather the necessary data to apply the DSM-5-TR criteria over time. This requires moving beyond a simple symptom checklist to a forensic-level investigation of the patient's life, mapping the trajectory of substance use against the evolution of their mental state.

### **Recommendations for Clinicians**

Based on the evidence reviewed, the following recommendations can guide clinical practice in this challenging area:

1. **Maintain a Provisional Stance:** Approach the initial diagnosis in any patient with new-onset psychosis and concurrent substance use with a high index of suspicion for both SIPD and an emerging primary disorder. Treat the initial diagnosis as a working hypothesis to be tested over time.
2. **Prioritize Collateral History:** Recognize the limitations of the patient's self-report and toxicology screens in the acute phase. Actively and persistently seek collateral information from family, friends, and previous providers to establish a reliable timeline of substance use, premorbid functioning, and symptom onset. This is often the most valuable source of diagnostic information.
3. **Utilize Hospitalization as a Diagnostic Tool:** When inpatient admission is necessary for stabilization, leverage this as a crucial opportunity for diagnostic clarification. The controlled environment allows for observation of the patient's clinical course during a period of forced abstinence, which can provide the most definitive evidence for or against a primary psychotic disorder.
4. **Implement Assertive Longitudinal Follow-Up:** The high rate of diagnostic conversion necessitates close monitoring after discharge. For any patient diagnosed with SIPD, especially if induced by high-risk substances like cannabis, amphetamines, or hallucinogens, arrange for assertive follow-up for a minimum of two to five years.<sup>9</sup> These patients should be considered a "clinical high-risk" population for developing schizophrenia.
5. **Educate Patients and Families:** Provide clear education to patients and their families about the nature of the diagnostic uncertainty. Explain the rationale for a provisional diagnosis and the critical importance of sustained abstinence and ongoing monitoring. Discuss the risk of conversion to a chronic illness like schizophrenia, as this can enhance motivation for substance use treatment and engagement in follow-up care.
6. **Adopt a Structured Assessment Logic:** Even without formal instruments, structure the clinical interview to first build a comprehensive substance use history and timeline. Only then should the psychotic symptoms be evaluated in the context of that timeline. This systematic approach helps to mitigate cognitive biases and ensures that a substance-induced etiology is thoroughly considered before concluding the psychosis is primary.

## Future Directions

While the current clinical framework provides a robust methodology for this differential diagnosis, significant challenges remain. The diagnostic process is still heavily reliant on historical report and clinical observation, which can be unreliable. Future research should focus on identifying objective biomarkers—whether genetic, neuroimaging, or inflammatory markers—that could help differentiate individuals with a transient SIPD from those with an underlying vulnerability to a primary psychotic disorder at the time of their first presentation.<sup>15</sup> Further large-scale, prospective longitudinal studies are needed to refine our understanding of substance-specific conversion risks and to develop more

targeted early intervention strategies for those identified as being at highest risk. By continuing to investigate the complex interplay between substance use and the neurobiology of psychosis, the field can move toward a more precise and predictive diagnostic paradigm, ultimately improving outcomes for this vulnerable patient population.

## Works cited

1. Substance Use Disorder Among People With First-Episode Psychosis: A Systematic Review of Course and Treatment | Psychiatric Services - Psychiatry Online, accessed on August 30, 2025,  
[https://psychiatryonline.org/doi/10.1176/ps.62.9.pss6209\\_1007](https://psychiatryonline.org/doi/10.1176/ps.62.9.pss6209_1007)
2. Differences Between Early-Phase Primary Psychotic Disorders With Concurrent Substance Use and Substance-Induced Psychoses - Columbia University, accessed on August 30, 2025,  
<http://www.columbia.edu/~dsh2/pdf/Caton2005.pdf>
3. Substance-Induced Psychoses: An Updated Literature Review - Frontiers, accessed on August 30, 2025,  
<https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsy.2021.694863/full>
4. Beyond the High: The Dual Challenge of Substance Use and Psychotic Symptoms - Kevin William Grant—Registered Psychotherapist, accessed on August 30, 2025,  
<https://www.kevinwgrant.com/blog/item/dual-challenge-of-substance-use-and-psychotic-symptoms>
5. Assessing the utility of drug screening in the emergency: a short report | BMJ Open Quality, accessed on August 30, 2025,  
<https://bmjopenquality.bmj.com/content/7/4/e000414>
6. Substance Induced Psychosis in First Episode Programming - nri-inc.org, accessed on August 30, 2025,  
[https://nri-inc.org/media/1574/nri\\_substance\\_induced\\_psychosis\\_fep.pdf](https://nri-inc.org/media/1574/nri_substance_induced_psychosis_fep.pdf)
7. Primary psychosis with comorbid drug abuse and drug-induced psychosis: diagnostic and clinical evolution at follow up, accessed on August 30, 2025,  
[https://kclpure.kcl.ac.uk/portal/files/67638179/Primary\\_psychosis\\_with\\_comorbid\\_MAURI\\_Publishedonline2May2017\\_GREEN\\_AAM\\_CC\\_BY\\_NC\\_ND\\_.pdf](https://kclpure.kcl.ac.uk/portal/files/67638179/Primary_psychosis_with_comorbid_MAURI_Publishedonline2May2017_GREEN_AAM_CC_BY_NC_ND_.pdf)
8. Substance-Induced Psychosis: An Indicator of Development of Primary Psychosis? | American Journal of Psychiatry, accessed on August 30, 2025,  
<https://psychiatryonline.org/doi/10.1176/appi.ajp.2018.17121395>
9. Risk of transition to schizophrenia following first admission with substance-induced psychotic disorder: a population-based longitudinal cohort study | Psychological Medicine, accessed on August 30, 2025,  
<https://www.cambridge.org/core/journals/psychological-medicine/article/risk-of-transition-to-schizophrenia-following-first-admission-with-substanceinduced-psychotic-disorder-a-populationbased-longitudinal-cohort-study/60E022FAFCBF699311471405EC4561CF>
10. When Cannabis Use Goes Wrong: Mental Health Side Effects of Cannabis Use That Present to Emergency Services - Frontiers, accessed on August 30, 2025,  
<https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsy.2021.640222/full>

11. Screening for substance use disorders in first-episode psychosis: Implications for readmission - PMC, accessed on August 30, 2025,  
<https://PMC.ncbi.nlm.nih.gov/articles/PMC4390132/>
12. The Big Picture: The Importance of Comprehensive Toxicology Testing in Understanding and Addressing Mental Health in Courts - American Bar Association, accessed on August 30, 2025,  
<https://www.americanbar.org/groups/judicial/resources/highway-justice/importance-comprehensive-toxicology-testing/>
13. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses - PubMed, accessed on August 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/15699290/>
14. Diagnostic stability in substance-induced psychosis | Revista de Psiquiatría y Salud Mental (English Edition) - Elsevier, accessed on August 30, 2025,  
<https://www.elsevier.es/en-revista-revista-psiquiatria-salud-mental-486-articulo-diagnostic-stability-in-substance-induced-psychosis-S2173505022000681>
15. Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis | The British Journal of Psychiatry, accessed on August 30, 2025,  
<https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/stability-of-earlyphase-primary-psychotic-disorders-with-concurrent-substance-use-and-substanceinduced-psychosis/9581085C6C56AC0FD77FB0E15C500058>
16. What is Schizophrenia? - Psychiatry.org, accessed on August 30, 2025,  
<https://www.psychiatry.org/patients-families/schizophrenia/what-is-schizophrenia>
17. Schizophrenia: Practice Essentials, Background, Pathophysiology - Medscape Reference, accessed on August 30, 2025,  
<https://emedicine.medscape.com/article/288259-overview>
18. Diagnostic stability in substance-induced psychosis | Revista de Psiquiatría y Salud Mental (English Edition) - Elsevier, accessed on August 30, 2025,  
<https://www.elsevier.es/es-revista-revista-psiquiatria-salud-mental-486-articulo-diagnostic-stability-in-substance-induced-psychosis-S2173505022000681>
19. Table 3.20, DSM-IV to DSM-5 Psychotic Disorders - Impact of the ..., accessed on August 30, 2025,  
<https://www.ncbi.nlm.nih.gov/books/NBK519704/table/ch3.t20/>
20. Substance- or Medication-Induced Psychotic Disorder - Psychiatric ..., accessed on August 30, 2025,  
<https://www.msdmanuals.com/professional/psychiatric-disorders/schizophrenia-and-related-disorders/substance-or-medication-induced-psychotic-disorder>
21. Substance/Medication-Induced Psychotic Disorder | Abnormal Psychology, accessed on August 30, 2025,  
<https://courses.lumenlearning.com/wm-abnormalpsych/chapter/substance-m medication-induced-psychotic-disorder/>
22. DSM-5 Table of Contents - American Psychiatric Association, accessed on August 30, 2025,  
[https://www.psychiatry.org/File%20Library/Psychiatrists/Practice/DSM/APA\\_DSM-5-Contents.pdf](https://www.psychiatry.org/File%20Library/Psychiatrists/Practice/DSM/APA_DSM-5-Contents.pdf)

23. DSM-5 Criteria: Schizophrenia - Florida Program for Behavioral Health Improvements and Solutions, accessed on August 30, 2025,  
[https://floridabhcenter.org/wp-content/uploads/2021/03/Pages-2019-Psychot%20herapeutic-Medication-Guidelines-for-Adults\\_Schizophrenia\\_06-04-20.pdf](https://floridabhcenter.org/wp-content/uploads/2021/03/Pages-2019-Psychot%20herapeutic-Medication-Guidelines-for-Adults_Schizophrenia_06-04-20.pdf)
24. Schizophreniform Disorder: Causes, Symptoms, Treatment DSM-5 295.40 (F20.81), accessed on August 30, 2025,  
<https://thriveworks.com/blog/schizophreniform-disorder/>
25. Schizophreniform Disorder - PsychDB, accessed on August 30, 2025,  
<https://www.psychdb.com/psychosis/schizophreniform>
26. Schizophreniform Disorder: Practice Essentials, Background, Pathophysiology, accessed on August 30, 2025,  
<https://emedicine.medscape.com/article/2008351-overview>
27. Schizoaffective Disorder - PsychDB, accessed on August 30, 2025,  
<https://www.psychdb.com/psychosis/schizoaffective>
28. Schizoaffective Disorder: Practice Essentials, Background, Epidemiology, accessed on August 30, 2025,  
<https://emedicine.medscape.com/article/294763-overview>
29. Forensic Considerations of Substance-Induced Psychosis, accessed on August 30, 2025, <https://jaapl.org/content/41/2/168>
30. Table 3.22, DSM-IV to DSM-5 Schizophrenia Comparison - NCBI, accessed on August 30, 2025,  
<https://www.ncbi.nlm.nih.gov/books/NBK519704/table/ch3.t22/>
31. substance use psychosis + - National Drug & Alcohol Research Centre, accessed on August 30, 2025,  
[https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/NDARC\\_PYC\\_HOSIS\\_FINAL.pdf](https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/NDARC_PYC_HOSIS_FINAL.pdf)
32. Substance Use Disorder (SUD): Symptoms & Treatment - Cleveland Clinic, accessed on August 30, 2025,  
<https://my.clevelandclinic.org/health/diseases/16652-drug-addiction-substance-use-disorder-sud>
33. Stimulant Psychosis: Symptom Profile and Acute Clinical Course, accessed on August 30, 2025,  
<https://www.tandfonline.com/doi/pdf/10.1080/10550490050172209>
34. An outline about Psychiatric history within informal assessments - Comorbidity Guidelines, accessed on August 30, 2025,  
<https://comorbidityguidelines.org.au/informal-assessment/psychiatric-history>
35. Toxicology Screen: Types, Uses & Drug Detection | Danaher Life Sciences, accessed on August 30, 2025,  
<https://lifesciences.danaher.com/us/en/library/toxicology-screen.html>
36. Schizophrenia: What It Is, Causes & Symptoms - Cleveland Clinic, accessed on August 30, 2025,  
<https://my.clevelandclinic.org/health/diseases/4568-schizophrenia>
37. Differentiating first episode substance induced and primary psychotic disorders with concurrent substance use in young people - PubMed, accessed on August 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/22321667/>
38. How does a family history of psychosis influence the risk of methamphetamine-related psychotic symptoms: Evidence from longitudinal panel data, accessed on August 30, 2025,

<https://pmc.ncbi.nlm.nih.gov/articles/PMC10952942/>

39. Comparison between substance-induced psychosis and primary psychosis, accessed on August 30, 2025,  
<https://applications.emro.who.int/imemrf/451/Tanta-Med-J-2019-47-2-62-67-eng.pdf>
40. Structured Clinical Interview for the DSM-5 (SCID PTSD Module), accessed on August 30, 2025,  
<https://www.ptsd.va.gov/professional/assessment/adult-int/scid-ptsd-module.asp>
41. Psychometric properties of Structured Clinical Interview for DSM-5 Disorders-Clinician Version (SCID-5-CV) - PMC, accessed on August 30, 2025,  
<https://pmc.ncbi.nlm.nih.gov/articles/PMC8119811/>
42. Substance-induced psychotic disorder - Comorbidity Guidelines, accessed on August 30, 2025,  
<https://comorbidityguidelines.org.au/what-are-substance-induced-disorders/substanceinduced-psychotic-disorder>
43. Substance-Induced Psychosis: Symptoms, Causes, and Treatment, accessed on August 30, 2025,  
<https://americanaddictioncenters.org/health-complications-addiction/drug-induced-psychosis>
44. A Comparison of Methamphetamine-Induced Psychosis and Schizophrenia: A Review of Positive, Negative, and Cognitive Symptomatology - PMC - PubMed Central, accessed on August 30, 2025,  
<https://pmc.ncbi.nlm.nih.gov/articles/PMC6191498/>
45. Positive and negative symptoms in methamphetamine-induced psychosis compared to schizophrenia: A systematic review and meta-analysis - PubMed, accessed on August 30, 2025, <https://pubmed.ncbi.nlm.nih.gov/38554698/>
46. Clinical profile of cannabis-induced psychosis in comparison to schizophrenia | Request PDF - ResearchGate, accessed on August 30, 2025,  
[https://www.researchgate.net/publication/286226337\\_Clinical\\_profile\\_of\\_cannabis-induced\\_psychosis\\_in\\_comparison\\_to\\_schizophrenia](https://www.researchgate.net/publication/286226337_Clinical_profile_of_cannabis-induced_psychosis_in_comparison_to_schizophrenia)
47. Stimulant psychosis - Wikipedia, accessed on August 30, 2025,  
[https://en.wikipedia.org/wiki/Stimulant\\_psychosis](https://en.wikipedia.org/wiki/Stimulant_psychosis)
48. Clinical profile of cannabis-induced psychosis in comparison to schizophrenia - Psychiatry Research EG, accessed on August 30, 2025,  
[https://psychiatry-research-eq.com/texts/MECP/201410/Clinical\\_profile\\_of\\_cannabis\\_induced\\_psychosis\\_in.4.pdf](https://psychiatry-research-eq.com/texts/MECP/201410/Clinical_profile_of_cannabis_induced_psychosis_in.4.pdf)
49. Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis - PMC, accessed on August 30, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC7147575/>
50. Cannabis-induced psychosis masquerading schizophrenia or vice-versa? A diagnostic dilemma - PMC, accessed on August 30, 2025,  
<https://pmc.ncbi.nlm.nih.gov/articles/PMC8611560/>
51. Cannabis Induced Schizophrenia-Like Psychosis: A Comparative Study between Cannabis and Cocaine Use Disorder, accessed on August 30, 2025,  
<https://www.clinicalschizophrenia.net/articles/cannabis-induced-schizophrenia-like-psychosis-a-comparative-study-between-cannabis-and-cocaine-use-disorder-105699.html>

52. Drug-Induced Psychosis: Signs, Treatment, & Effects | Greenhouse, accessed on August 30, 2025,  
<https://greenhousetreatment.com/co-occurring-disorders/drug-induced-psychosis/>
53. Drug addiction (substance use disorder) - Symptoms and causes - Mayo Clinic, accessed on August 30, 2025,  
<https://www.mayoclinic.org/diseases-conditions/drug-addiction/symptoms-causes/syc-20365112>
54. Substance-Induced Psychosis: Diagnostic Challenges and Phenomenological Insights, accessed on August 30, 2025,  
<https://www.mdpi.com/2673-5318/5/4/52>
55. The need for close monitoring of early psychosis and co-occurring substance misuse | The Psychiatrist - Cambridge University Press, accessed on August 30, 2025,  
<https://www.cambridge.org/core/journals/the-psychiatrist/article/need-for-close-monitoring-of-early-psychosis-and-cooccurring-substance-misuse/EE25E98F0B91FDE89C54687D5E302B0F>
56. (PDF) Diagnostic stability in substance-induced psychosis - ResearchGate, accessed on August 30, 2025,  
[https://www.researchgate.net/publication/365439107\\_Diagnostic\\_stability\\_in\\_substance-induced\\_psychosis](https://www.researchgate.net/publication/365439107_Diagnostic_stability_in_substance-induced_psychosis)
57. Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample - Psychiatry Online, accessed on August 30, 2025,  
<https://psychiatryonline.org/doi/10.1176/appi.ajp.2019.18101217>
58. The Link Between Schizophrenia and Substance Use Disorder: A Unifying Hypothesis, accessed on August 30, 2025,  
<https://pmc.ncbi.nlm.nih.gov/articles/PMC6094954/>